Markets:

Overview

News

Currencies

International

Treasuries

Johnson & Johnson (NY:JNJ)

205.78 -1.54 (-0.74%)

Official Closing Price Updated: 4:00 PM EST, Dec 23, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash ↗

April 10, 2025

Here's why the 90-day tariffs delay doesn't help pharmaceutical companies.

Via Investor's Business Daily

Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study ↗

April 10, 2025

Protagonist and Johnson & Johnson report positive Phase 3 data on icotrokinra in adolescent plaque psoriasis, showing high clearance rates and favorable safety.

Via Benzinga

Alphabet To $185? Here Are 10 Top Analyst Forecasts For Thursday ↗

April 10, 2025

Via Benzinga

If Your Portfolio Is Down on the Tariff News, Check Out This Little-Known High-Yield Dividend Stock ↗

April 10, 2025

Investors are dumping growth stocks right now as new tariff policies rock the markets.

Via The Motley Fool

Topics Artificial Intelligence Economy Government

Stock Market Sell-Off Shopping Spree: 3 Top Dividend Stocks I Just Bought to Boost My Passive Income ↗

April 10, 2025

Via The Motley Fool

Topics Bonds

The Dow Crashed 4,260 Points in 3 Days: Here Are 3 Dow Stocks That Make for No-Brainer Buys Right Now ↗

April 10, 2025

Three of the Dow's 30 components make for sensational buys amid a historic sell-off.

Via The Motley Fool

Topics Credit Cards Economy Stocks

This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine ↗

April 09, 2025

Goldman Sachs upgraded Johnson & Johnson (JNJ) from Neutral to Buy, citing underappreciated Innovative Medicine business and upcoming product cycles.

Via Benzinga

Tesla Underdelivers ↗

April 09, 2025

And we take a look at Texas Instruments and Taiwan Semiconductor.

Via The Motley Fool

Topics Government World Trade

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

Amazon.com To $255? Here Are 10 Top Analyst Forecasts For Wednesday ↗

April 09, 2025

Via Benzinga

This Apple Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday ↗

April 09, 2025

Via Benzinga

Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst ↗

April 08, 2025

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

Via Benzinga

Topics World Trade

As Trump Tariffs Spark Panic, Investors Rush Into These 5 'Recession-Proof' ETFs ↗

April 08, 2025

ETFs that provide exposure to sectors that have historically been considered defensive during downturns are now in the limelight.

Via Benzinga

Topics ETFs Government

Johnson & Johnson's New 'Compelling Data' Shows Sustained Symptom Improvement In Muscular Disease Patients ↗

April 08, 2025

Johnson & Johnson reports long-term efficacy and steroid-sparing benefits of nipocalimab in antibody-positive generalized myasthenia gravis.

Via Benzinga

Johnson & Johnson to Participate in the BofA Securities 2025 Healthcare Conference

April 07, 2025

From Johnson & Johnson

Via Business Wire

Why Health Care Select Sector SPDR Fund (XLV) Is Moving ↗

April 07, 2025

Shares of the Health Care Select Sector SPDR Fund are trading lower by 8.6% over the past week. Tariff announcements from President Donald Trump last week spooked investors and have dragged major...

Via Benzinga

Topics Government

All the Stocks Warren Buffett Bought in the Last 2 Recessions: Are They Smart Picks Now? ↗

April 06, 2025

Via The Motley Fool

Topics Economy Government World Trade

Amid Market Chaos, Don't Do This ↗

April 05, 2025

Markets are under some duress, but the action should not cause you to change your thesis. While markets are facing headwinds, it’s important to realize that stocks are under duress in what feels like a...

Via Talk Markets

Topics Stocks / Equities

President Trump's Tariffs Have Arrived. 3 Things to Do to Protect Your Portfolio. ↗

April 05, 2025

Via The Motley Fool

Topics Economy Government Stocks

Sit Out Market Drama With These 3 Dividend Funds ↗

April 04, 2025

Via Benzinga

Johnson & Johnson's Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study ↗

April 04, 2025

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients with no new safety concerns.

Via Benzinga

Trump's Tariff Exemptions Include Semiconductors, Pharmaceuticals, Oil And More ↗

April 03, 2025

President Donald Trump on Wednesday announced a slew of tougher-than-anticipated tariffs, but there are some notable exemptions to the steep levies. Here's a look at which products and sectors are...

Via Benzinga

Topics Government World Trade

Man With $30K To Deploy Wants Dividends For Life – 'Even If It's Just Enough To Pay For A Yearly Vacation Here Or There,' Reddit Reacts ↗

April 03, 2025

For many investors, dividend-focused stocks and funds provide a way to generate passive income, whether to supplement retirement, cover day-to-day

Via Benzinga

Topics Retirement

Worried About the Economy? 2 No-Brainer Buys to Shield Your Portfolio. ↗

April 02, 2025

Via The Motley Fool

Topics Earnings Economy Government

What 13 Analyst Ratings Have To Say About Johnson & Johnson ↗

April 02, 2025

Via Benzinga

Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended ↗

April 02, 2025

Shares of Johnson & Johnson (JNJ) sold off on news regarding a dilution of its earnings. The selloff ended when it reach support.

Via Benzinga

Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership

April 02, 2025

From Johnson & Johnson

Via Business Wire

J&J Retail Traders Unfazed By Court Rejecting 3rd Talc Settlement, But Analyst Sees Stock Pullback Risk ↗

April 01, 2025

According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug.

Via Stocktwits

Topics Bankruptcy Lawsuit

Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

April 01, 2025

U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07.

Via Benzinga

Topics Stocks

Uncover the latest developments among S&P500 stocks in today's session. ↗

April 01, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Johnson & Johnson (NY:JNJ)

All News about Johnson & Johnson

Starting at $3.75/week.

Subscribe Today